gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

Is neoadjuvant chemotherapy benefical in surgical treatment of rectal cancer?

Meeting Abstract

Suche in Medline nach

  • corresponding author presenting/speaker Johannes Ehrig - Paul-Gerhardt-Stift, Lutherstadt Wittenberg, Deutschland
  • A. Gabler - Paul-Gerhardt-Stift, Lutherstadt Wittenberg
  • J. Dunst - Klinik für Strahlentherapie, Halle
  • H. Zühlke - Paul-Gerhardt-Stift, Lutherstadt Wittenberg

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO402

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter:

Veröffentlicht: 20. März 2006

© 2006 Ehrig et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



Introduction: 5-year survival in rectal cancer is dependent on the occurrence of a local recurrence. It can be influenced on the one hand by exact adherence to surgical oncology practces, on the other hand by additional therapeutic regimes such as a combination of radiotherapy and systemic chemotherapy. Aside from timing, procedure of additional therapy and interval between radio-chemotherapy and surgical intervention, the following question question (issue) is in discussion: does neoadjuvant chemotherapy increase the rate of intra-surgical complications.

Material and methods: Experience is based a total of 20 patients: 11 patients participating in the Erlangen trial (combination of 5-FU and radiation), 6 patients enrolled in a Xeloda phase-II-trial and 3 patients from a pilot trial with oxaliplatin and Xeloda.

Results: All patients were judged as non-resectable based on an intensive pre-operative diagnostic regimen. Following neoadjuvant radio-chemotherapy, all patients could be treated surgically by TME-resection or amputation. Interventions were conducted by two surgeons. Intraoperative complications, which could be attributed to the neoadjuvant radio-chemotherapy, were not experienced in any of the patients. Pre-tumorous inflammation and tumor had regressed in all cases.

Conclusions: Intra-operative complications occurrred in none of the patients. Based on our experience, neoadjuvant radio-chemotherapy in its various modifictions does not constitute a hindrance for a radical surgical treatment.